Tanabe Pharma announced positive results from a Phase 3 clinical trial of its oral drug designed to treat rare diseases that cause pain upon light exposure. The achievement marks the company's first major clinical milestone since being acquired by Bain Capital.
The trial targeted a pair of rare photosensitive diseases, conditions that cause patients to experience pain when exposed to light. These disorders represent a significant unmet medical need with limited treatment options currently available for patients.